Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting | Zendy

Marco Valgimigli | Zendy; Gianluca Campo | Zendy; Monia Monti | Zendy; Pascal Vranckx | Zendy; Gianfranco Percoco | Zendy; Carlo Tumscitz | Zendy; Fausto Castriota | Zendy; Federico Colombo | Zendy; Matteo Tebaldi | Zendy; Giuseppe Fucă | Zendy; Moh’d Kubbajeh | Zendy; Elisa Cangiano | Zendy; Monica Minarelli | Zendy; Antonella Scalone | Zendy; Caterina Cavazza | Zendy; Alice Frangione | Zendy; Marco Borghesi | Zendy; Jlenia Marchesini | Zendy; Giovanni Parrinello | Zendy; Roberto Ferrari | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting

Author(s) -

Marco Valgimigli,

Gianluca Campo,

Monia Monti,

Pascal Vranckx,

Gianfranco Percoco,

Carlo Tumscitz,

Fausto Castriota,

Federico Colombo,

Matteo Tebaldi,

Giuseppe Fucă,

Moh’d Kubbajeh,

Elisa Cangiano,

Monica Minarelli,

Antonella Scalone,

Caterina Cavazza,

Alice Frangione,

Marco Borghesi,

Jlenia Marchesini,

Giovanni Parrinello,

Roberto Ferrari

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.071589

Subject(s) - medicine , clopidogrel , myocardial infarction , hazard ratio , zotarolimus , aspirin , regimen , population , stent , percutaneous coronary intervention , clinical endpoint , drug eluting stent , cardiology , surgery , confidence interval , randomized controlled trial , environmental health

The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal stents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research